Epidemiological and Clinical-pathological Factors of Philadelphia-negative Myeloproliferative Neoplasms in Ecuador

Sociedad de Lucha Contra el Cáncer del Ecuador40 enrolled

Overview

The goal of this observational study is to evaluate the epidemiological and clinical-pathological features of Philadelphia-negative myeloproliferative neoplasms through data from medical records

The investigators are proposing a study that provides descriptive understanding of patients with Philadelphia-negative myeloproliferative neoplasms in Ecuador. The primary objective of this pilot study is to lay the foundations for the development of a multicenter registry of Philadelphia-negative myeloproliferative neoplasms, which will provide high-quality real data and serve as a basis for the application to future projects and elaboration of public policies in the medium and long term.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Myeloproliferative Neoplasm Myeloproliferative Syndrome Myeloproliferative Neoplasm, Unclassifiable Myeloproliferative Disorders Myeloproliferative Disease, Not Classified

Medical Language ↔ Plain English

Inclusion Criteria: * 18 years and older * Patients with confirmed diagnosis of Philadelphia-negative Myeloproliferative Neoplasms Exclusion Criteria: * Patients with translocation t(9;22)(q34:q11.2) with subsequent formation of the BCR-ABL1 fusion gene determined by cytogenetics or fluorescence in situ hybridization (FISH) * Absence of the histopathological report in the clinical history and the corresponding plaque, except in the case of Polycythemia Vera that does not require them for diagnosis, according to the 2022 WHO classification

Outcomes

Primary Outcomes

Number of patients with Philadelphia-negative Myeloproliferative Neoplasms in Ecuador

Participants were followed-up for 8 years. This is the number of participants who have had Philadelphia-negative Myeloproliferative Neoplasms in Ecuador during the time of observation.

Time frame: 96 months

Secondary Outcomes

Prevalence of Philadelphia-negative myeloproliferative patients

Calculation of the prevalence of participants who have had Philadelphia-negative Myeloproliferative Neoplasms in Ecuador during the time of observation.

Time frame: 96 months

Mortality risk as measured by the Dynamic International Prognostic Scoring System

The Dynamic International Prognostic Scoring System (DIPSS) was proposed and validated by Passamonti and is used as a prognostic model to predict survival in participants with Primary Myeloid Fibrosis a Philadelphia-negative myeloproliferative neoplasm. Possible scores range from 0 to 6, with higher scores indicating higher mortality risk.

Time frame: 96 months

Overall survival

Percent of participants with Primary Myeloid Fibrosis who were alive at 96 months of follow-up

Time frame: 96 months

Epidemiological and Clinical-pathological Factors of Philadelphia-negative Myeloproliferative Neoplasms in Ecuador

Overview

Conditions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes